New reports from ECCMID 2022 shed light on the disease burden of RSV in older adults, as well as the impact of the COVID-19 pandemic on seasonal trends in RSV.
There has never been a more promising time in the field of RSV for older adults than now, with the exciting preventive therapies on the horizon.
A new vaccine candidate for prevention of RSV in older adults was added to the EMA’s PRIME scheme. Here’s my summary of the key clinical trial information.
Read my commentary on how RSV can have a detrimental impact on quality of life, especially in older adults.
Learn from a leading expert about RSV in older adults, including epidemiology and reasons older adults are at increased risk compared with their younger counterparts.
Learn from a leading expert about RSV in older adults, including epidemiology and reasons older adults are at increased risk compared with their younger counterparts.
Learn from a leading expert about strategies for overcoming difficulties related to the diagnosis and impact of RSV in older adults.
Learn from a leading expert about strategies for overcoming difficulties related to the diagnosis and impact of RSV in older adults.
Learn from a leading expert about RSV immunology and the current status of the most promising vaccines in development for older adults.
Learn from a leading expert about RSV immunology and the current status of the most promising vaccines in development for older adults.
Learn from a leading expert about RSV in older adults, including epidemiology, risk for severe outcomes, identification, and vaccines in development.
RSV is not just a childhood illness. Learn from a leading expert about RSV in older adults, including epidemiology and reasons older adults are at increased risk compared with their younger counterparts.
Learn from a leading expert about strategies for overcoming difficulties related to the diagnosis and impact of RSV in older adults.
Learn from a leading expert about RSV immunology, the economic burden of RSV, and the current status of the most promising vaccines in development for older adults.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.